{
  "guideline": {
    "id": "PA166182842",
    "name": "Annotation of DPWG Guideline for warfarin and CYP2C9",
    "source": "DPWG",
    "version": 7,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182842",
    "relatedChemicals": [
      {
        "id": "PA451906",
        "name": "warfarin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299075",
      "name": "Recommendation PA166299075",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061438,
        "html": "<p>The guideline does not provide a recommendation for warfarin in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on warfarin."
      ],
      "lookupKey": {
        "CYP2C9": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299071",
      "name": "Recommendation PA166299071",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061434,
        "html": "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*2": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299074",
      "name": "Recommendation PA166299074",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061437,
        "html": "<ol>\n<li>use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *2 or *3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</li>\n</ol>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding."
      ],
      "lookupKey": {
        "CYP2C9": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299070",
      "name": "Recommendation PA166299070",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061433,
        "html": "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299073",
      "name": "Recommendation PA166299073",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061436,
        "html": "<ol>\n<li>use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299069",
      "name": "Recommendation PA166299069",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061432,
        "html": "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *1/*2 or *1/*3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</li>\n</ol>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding."
      ],
      "lookupKey": {
        "CYP2C9": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299072",
      "name": "Recommendation PA166299072",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061435,
        "html": "<ol>\n<li>use 45% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*2": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299068",
      "name": "Recommendation PA166299068",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061431,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "Genetic variation may lead to a decrease in the required maintenance dose. However, there is insufficient evidence that this causes problems when therapy is initiated as usual."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*2": 1.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2023-12-19-10-38"
}